Eliglustat drug class?

What drug class is eliglustat (Cerdelga) in?

Eliglustat is a glucosylceramide synthesis inhibitor (an enzyme inhibitor) used for treating Gaucher disease type 1. It works by blocking glucosylceramide synthase, which reduces the production of glucosylceramide that builds up in people with Gaucher disease.

What is the mechanism of action behind eliglustat’s drug class?

As a glucosylceramide synthesis inhibitor, eliglustat targets the enzyme glucosylceramide synthase. By inhibiting that enzyme, it lowers synthesis of glucosylceramide and helps reduce substrate accumulation associated with Gaucher disease type 1.

Where does eliglustat fit versus other Gaucher disease treatments?

Eliglustat is an oral, disease-specific therapy that targets glucosylceramide synthesis. This is different from enzyme replacement therapies (ERT), which supply the missing or deficient enzyme rather than inhibiting lipid synthesis.

Important prescribing context for this class (metabolism and drug interactions)

Eliglustat has clinically important metabolism considerations because it is processed via CYP pathways (and can be affected by other drugs that inhibit or induce those enzymes). That metabolism affects eligibility by genotype and influences which patients can use it safely.

Patents and related exclusivity tracking

For updates on patent and exclusivity status tied to eliglustat, DrugPatentWatch.com can be used as a reference point: https://www.drugpatentwatch.com/